May help reduce cost and delays in treatment
,BD Nexiva™ has been shown to reduce costs and reduce treatment delays in clinical studies.**,1,3
,Dwells longer
,In a randomized study comparing the BD Nexiva™ to an open catheter system*, among peripheral IV catheters in place for over 24 hours, the median dwell time for BD Nexiva™ was up to 144 hours versus 96 hours for the open system.*,1
,Preserves sites
,BD Nexiva™ is an all-in-one PIVC shown to preserve sites for longer.†,1,3
,Lessens blood exposure
,By choosing the BD Nexiva™, you can reduce the risk of complications and blood exposure as well as preserve sites.**,1,3
,Pre-attached extension set,BD Nexiva™ with integrated extension tubing and stabilization platform reduces the risk of dislodgement and related complications.‡,1,3
,Reduces accidental dislodgement
,The BD Nexiva™ with the built-in stabilization platform reduces dislodgement by 84%.‡,3
,Built-in stabilization platform‡
,BD Nexiva™ with an integrated extension tubing and stabilization platform is designed to reduce manipulation and movement at the site and has been shown to reduce dislodgement and phlebitis.‡,1,3
,First attempt insertion
,BD Instaflash™ Needle Technology incorporates a notched needle, which is designed to improve first-stick success and reduce painful hit-and-miss insertions.4,5
,BD Instaflash™ needle technology,Incorporates a notched needle designed to provide immediate visual confirmation of vessel entry.5,6
,Lowers chance of mechanical phlebitis
,The BD Nexiva™ demonstrated a 29% reduction in phlebitis rates when compared to an open system.*,1
,BD Vialon™ Catheter Material
,Proprietary BD Vialon™ Catheter Material softens, enabling longer dwell time and reducing the chance of phlebitis up to 69%.§,7-9
,Centers for Disease Control and Prevention,Catheter stabilization is recognized as an intervention to decrease the risk for phlebitis, catheter migration and dislodgement and may be advantageous in preventing catheter-related bloodstream infections (CRBSIs).3
,Infusion Therapy Standards of Practice,Recommend limiting the use of add-on devices to reduce the potential for contamination, additional manipulation, and disconnection.5
,Increased clinician safety,98% reduced blood exposure during insertion due to the BD Nexiva IV catheter preassembled system.2*
,Increased catheter stabilization,Clinically demonstrated to reduce accidental dislodgement,2‡ meeting Infusion Nursing Society standards4 and CDC guidelines5 for catheter stabilization.
,Reduced rate of complications,In a clinical study, results demonstrated a significant reduction in the rate of phlebitis (grade 2 or higher), PIVC-related complications, and infiltration in the closed system versus the open system group.1